Vimarsana
Biggest News Aggregation in the World

Page 2 - Patrick Burnett News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Patrick Burnett. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Patrick Burnett Today - Breaking & Trending Today

Vast Majority of Atopic Dermatitis Patients Show EASI Improvement with 4 Weeks of Roflumilast Cream - Vimarsana News

Vast Majority of Atopic Dermatitis Patients Show EASI Improvement with 4 Weeks of Roflumilast Cream

These data, presented at the Winter Clinical conference, showed that roflumilast cream 0.15% led to positive results for patients with eczema.

Roflumilast Foam Effective for Seborrheic Dermatitis Patients Inadequately Responding to Steroids - Vimarsana News

Roflumilast Foam Effective for Seborrheic Dermatitis Patients Inadequately Responding to Steroids

In this subgroup analysis data shown at Winter Clinical, findings indicated IGA success with topical roflumilast foam among seborrheic dermatitis patients.

Patrick Burnett Sells 23,000 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock - Vimarsana News

Patrick Burnett Sells 23,000 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) insider Patrick Burnett sold 23,000 shares of Arcutis Biotherapeutics stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $8.75, for a total transaction of $201,250.00. Following the completion of the sale, the insider now owns 209,793 shares of the […]

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Patrick Burnett Sells 23,000 Shares - Vimarsana News

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Patrick Burnett Sells 23,000 Shares

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) insider Patrick Burnett sold 23,000 shares of the stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $8.75, for a total value of $201,250.00. Following the sale, the insider now directly owns 209,793 shares of the company’s […]

Source: wkrb13.com
FDA Approves Foam to Treat Scalp Eczema in Children and Adults - Vimarsana News

FDA Approves Foam to Treat Scalp Eczema in Children and Adults

The new nonsteroidal drug, Zoryve, can relieve itching and swelling on the skin and scalp.